Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection

Journal of Infectious Diseases

Volumn 203, Issue 8, 2011, Pages 1063-1072

  Ibañez, Lorena Itatí ^a,b   De Filette, Marina ^a,b   Hultberg, Anna ^d   Verrips, Theo ^d   Temperton, Nigel ^e,f   Weiss, Robin A ^e   Vandevelde, Wesley ^c   Schepens, Bert ^a,b   Vanlandschoot, Peter ^c   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c ABLYNX NV   (Belgium)

^d UTRECHT UNIVERSITY   (Netherlands)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT INFLUENZA H5N1 HEMAGGLUTININ NANOBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG EFFICACY; EPITOPE MAPPING; FEMALE; IN VITRO STUDY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; FEMALE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NANOCAPSULES; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN CONFORMATION; SPECIFIC PATHOGEN-FREE ORGANISMS; TIME FACTORS;

EID: 79953318592     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq168     Document Type: Article

References (50)

1. de Jong MD. H5N1 transmission and disease: observations from the frontlines. Pediatr Infect Dis J 2008; 27:S54-6.
2. Nicholson KG. Aoki FY. Osterhaus AD. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-50. (Pubitemid 30311875)
3. Gu J. Xie Z. Gao Z. et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 2007; 370:1137-45. (Pubitemid 47464584)
4. Matrosovich MN. Matrosovich TY. Gray T. Roberts NA. Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 2004; 101:4620-4. (Pubitemid 38437460)
5. Rimmelzwaan GF. Nieuwkoop NJ. de Mutsert G. et al. Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry. Virus Res 2007; 129:175-81.
6. Govorkova EA. Ilyushina NA. Boltz DA. Douglas A. Yilmaz N. Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007; 51:1414-24. (Pubitemid 46586824)
7. de Jong MD. Tran TT. Truong HK. et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
8. Gooskens J. Jonges M. Claas EC. Meijer A. Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:1435-41.
9. de Jong MD. Simmons CP. Thanh TT. et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7. (Pubitemid 44527358)
10. Baskin CR. Bielefeldt-Ohmann H. Tumpey TM. et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 2009; 106:3455-60.
11. Salomon R. Hoffmann E. Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A 2007; 104:12479-81. (Pubitemid 47206163)
12. White NJ. Webster RG. Govorkova EA. Uyeki TM. What is the optimal therapy for patients with H5N1 influenza? PLoS Med 2009; 6:e1000091.
13. Zheng BJ. Chan KW. Lin YP. et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 2008; 105:8091-6.
14. Luke TC. Kilbane EM. Jackson JL. Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
15. Ross CW. Hund EJ. Treatment of the pneumonic disturbance complicating influenza, the transfusion of citrated immune blood. J Am Med Assoc 1919; 72:640-45.
16. Zhou B. Zhong N. Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450-1. (Pubitemid 47535608)
17. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57.
18. Marasco WA. Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25:1421-34. (Pubitemid 350233138)
19. Holliger P. Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36. (Pubitemid 41486394)
20. Greenberg AS. Avila D. Hughes M. Hughes A. McKinney EC. Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995; 374:168-73.
21. Hamers-Casterman C. Atarhouch T. Muyldermans S. et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446-8. (Pubitemid 23179389)
22. De Genst E. Silence K. Decanniere K. et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A 2006; 103:4586-91.
23. Baral TN. Magez S. Stijlemans B. et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med 2006; 12:580-4.
24. Coppieters K. Dreier T. Silence K. et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collageninduced arthritis. Arthritis Rheum 2006; 54:1856-66. (Pubitemid 43877935)
25. Cortez-Retamozo V. Backmann N. Senter PD. et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004; 64:2853-7. (Pubitemid 38500625)
26. De Haard HJ. Bezemer S. Ledeboer AM. et al. Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J Bacteriol 2005; 187:4531-41. (Pubitemid 40880965)
27. Dumoulin M. Last AM. Desmyter A. et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 2003; 424:783-8. (Pubitemid 37021708)
28. Roovers RC. Laeremans T. Huang L. et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007; 56:303-17. (Pubitemid 46035901)
29. Reed LJ. Muench H. A simple method for estimating fifty percent endpoints. Am J Med Hyg 1938; 27:493-7.
30. Stech J. Stech O. Herwig A. et al. Rapid and reliable universal cloning of influenza A virus genes by target-primed plasmid amplification. Nucleic Acids Res 2008; 36:e139.
31. Yamada S. Suzuki Y. Suzuki T. et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 2006; 444:378-82. (Pubitemid 44764114)
32. Hensley SE. Das SR. Bailey AL. et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009; 326:734-6.
33. Wiley DC. Wilson IA. Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373-8.
34. Perdue ML. Suarez DL. Structural features of the avian influenza virus hemagglutinin that influence virulence. Vet Microbiol 2000; 74:77-86. (Pubitemid 30224646)
35. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009; 49:279-90.
36. Sun L. Lu X. Li C. et al. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 2009; 4:e5476.
37. Chen Y. Qin K. Wu WL. et al. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 2009; 199:49-58.
38. Hanson BJ. Boon AC. Lim AP. Webb A. Ooi EE. Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7:126.
39. Maneewatch S. Thanongsaksrikul J. Songserm T. et al. Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1. Antivir Ther 2009; 14:221-30.
40. Simmons CP. Bernasconi NL. Suguitan AL. et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e178.
41. Corti D. Suguitan AL Jr. Pinna D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73.
42. Ekiert DC. Bhabha G. Elsliger MA. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-51.
43. Kashyap AK. Steel J. Oner AF. et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 2008; 105:5986-1.
44. Okuno Y. Isegawa Y. Sasao F. Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67:2552-8. (Pubitemid 23118850)
45. Saerens D. Ghassabeh GH. Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8:600-8.
46. Huang L. Gainkam LO. Caveliers V. et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008; 10:167-75.
47. Klasse PJ. Sattentau QJ. Mechanisms of virus neutralization by antibody. Curr Top Microbiol and Immunol 2001; 260:87-108. (Pubitemid 32577059)
48. Wang P. Yang X. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins. J Virol 2010; 84:7114-23.
49. Suarez DL. Perdue ML. Cox N. et al. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol 1998; 72:6678-88. (Pubitemid 28323986)
50. Matrosovich M. Zhou N. Kawaoka Y. Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 1999; 73:1146-55. (Pubitemid 29036766)